A new treatment to restore blood vessels in the eye for patients with vision loss.
Noregen, a regenerative medicine ocular therapeutic
This study is testing a new treatment called Noregen that aims to help people with eye conditions that can cause blindness by using a special growth factor to heal damaged blood vessels in the retina, potentially improving their vision and slowing down the disease.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Retinal Solutions LLC NIH-funded |
| Lab location | 1 site (Rochester, UNITED STATES) |
| Project ID | NIH-10877981 on NIH RePORTER |
What this research studies
This research focuses on developing Noregen, a regenerative medicine therapy aimed at treating ischemic retinopathies, which are conditions that can lead to blindness. The approach involves using a growth factor derived from norrin to restore the integrity of damaged blood vessels in the retina, promoting the regeneration of healthy capillaries. The research will optimize the dosing of intravitreal injections and conduct pharmacokinetics studies to support future FDA submissions. Patients may benefit from a therapy that not only slows disease progression but also repairs damaged retinal structures.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from ischemic retinopathies, such as diabetic retinopathy or retinal vein occlusion.
Not a fit: Patients with non-ischemic eye conditions or those who do not have retinal damage may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a novel therapy that restores vision by repairing damaged blood vessels in the retina.
How similar studies have performed: Previous research has shown promise in using growth factors for retinal repair, indicating potential success for this novel approach.
Where this research is happening
Rochester, UNITED STATES
- Retinal Solutions LLC — Rochester, United States (Active)
Researchers
- Principal investigator: Drenser, Kimberly — Retinal Solutions LLC
- Study coordinator: Drenser, Kimberly
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.